618 related articles for article (PubMed ID: 31477168)
1. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2
Clark AS; Yau C; Wolf DM; Petricoin EF; van 't Veer LJ; Yee D; Moulder SL; Wallace AM; Chien AJ; Isaacs C; Boughey JC; Albain KS; Kemmer K; Haley BB; Han HS; Forero-Torres A; Elias A; Lang JE; Ellis ED; Yung R; Tripathy D; Nanda R; Wulfkuhle JD; Brown-Swigart L; Gallagher RI; Helsten T; Roesch E; Ewing CA; Alvarado M; Crane EP; Buxton M; Clennell JL; Paoloni M; Asare SM; Wilson A; Hirst GL; Singhrao R; Steeg K; Asare A; Matthews JB; Berry S; Sanil A; Melisko M; Perlmutter J; Rugo HS; Schwab RB; Symmans WF; Hylton NM; Berry DA; Esserman LJ; DeMichele AM
Nat Commun; 2021 Nov; 12(1):6428. PubMed ID: 34741023
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot X; Burris H; Petersen JA; Stanzel S; Strasak A; Patre M; Ellis P
J Clin Oncol; 2017 Jan; 35(2):141-148. PubMed ID: 28056202
[TBL] [Abstract][Full Text] [Related]
4. Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial.
Weiss A; Jin Q; Waks AG; Yardley D; Spring LM; Wrabel E; Tayob N; Viale G; Krop IE; King TA; Metzger-Filho O
J Am Coll Surg; 2024 Mar; 238(3):303-311. PubMed ID: 38047578
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
Loibl S; de la Pena L; Nekljudova V; Zardavas D; Michiels S; Denkert C; Rezai M; Bermejo B; Untch M; Lee SC; Turri S; Urban P; Kümmel S; Steger G; Gombos A; Lux M; Piccart MJ; Von Minckwitz G; Baselga J; Loi S
Eur J Cancer; 2017 Nov; 85():133-145. PubMed ID: 28923573
[TBL] [Abstract][Full Text] [Related]
6. Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.
Yardley DA; Hart L; Bosserman L; Salleh MN; Waterhouse DM; Hagan MK; Richards P; DeSilvio ML; Mahoney JM; Nagarwala Y
Breast Cancer Res Treat; 2013 Jan; 137(2):457-64. PubMed ID: 23224144
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.
Gluz O; Nitz UA; Christgen M; Kuemmel S; Holtschmidt J; Schumacher J; Hartkopf A; Potenberg J; Lüedtke-Heckenkamp K; Just M; Schem C; von Schumann R; Kolberg-Liedtke C; Eulenburg CZ; Schinköthe T; Graeser M; Wuerstlein R; Kates RE; Kreipe HH; Harbeck N
JAMA Oncol; 2023 Jul; 9(7):946-954. PubMed ID: 37166817
[TBL] [Abstract][Full Text] [Related]
8. NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Jacobs SA; Wang Y; Abraham J; Feng H; Montero AJ; Lipchik C; Finnigan M; Jankowitz RC; Salkeni MA; Maley SK; Puhalla SL; Piette F; Quinn K; Chang K; Nagy RJ; Allegra CJ; Vehec K; Wolmark N; Lucas PC; Srinivasan A; Pogue-Geile KL
Breast Cancer Res; 2024 Apr; 26(1):69. PubMed ID: 38650031
[TBL] [Abstract][Full Text] [Related]
9. Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.
Holmes FA; Espina V; Liotta LA; Nagarwala YM; Danso M; McIntyre KJ; Osborne CR; Anderson T; Krekow L; Blum JL; Pippen J; Florance A; Mahoney J; O'Shaughnessy JA
BMC Res Notes; 2013 Dec; 6():507. PubMed ID: 24304724
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial.
Khattak MN; Chichura AM; Lang JE
Ann Surg Oncol; 2024 Mar; 31(3):1423-1427. PubMed ID: 38127215
[TBL] [Abstract][Full Text] [Related]
11. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study).
Antolín Novoa S; Escrivá-de-Romaní S; Tolosa Ortega P; Oliva Fernández L; López López R; López González A; de la Morena Barrio P; Echavarria Díaz-Guardamino I; Alés Martinez JE; Garate Z; González-Cortijo L
Cancer Treat Res Commun; 2023; 37():100772. PubMed ID: 37995519
[TBL] [Abstract][Full Text] [Related]
12. Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine
Wang X; Li W; Yin Y; Tong Z; Zhang Q; Zheng H; Shao Z; Li H; Yang J; Feng J; Wu F; Lamour F; Restuccia E; Jiang Z
Transl Breast Cancer Res; 2023; 4():3. PubMed ID: 38751488
[TBL] [Abstract][Full Text] [Related]
13. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial.
Sartore-Bianchi A; Lonardi S; Martino C; Fenocchio E; Tosi F; Ghezzi S; Leone F; Bergamo F; Zagonel V; Ciardiello F; Ardizzoni A; Amatu A; Bencardino K; Valtorta E; Grassi E; Torri V; Bonoldi E; Sapino A; Vanzulli A; Regge D; Cappello G; Bardelli A; Trusolino L; Marsoni S; Siena S
ESMO Open; 2020 Sep; 5(5):e000911. PubMed ID: 32988996
[TBL] [Abstract][Full Text] [Related]
14. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Swain SM; Ewer MS; Viale G; Delaloge S; Ferrero JM; Verrill M; Colomer R; Vieira C; Werner TL; Douthwaite H; Bradley D; Waldron-Lynch M; Kiermaier A; Eng-Wong J; Dang C;
Ann Oncol; 2018 Mar; 29(3):646-653. PubMed ID: 29253081
[TBL] [Abstract][Full Text] [Related]
15. The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial.
Zhu Y; Zerdes I; Matikas A; Cruz IR; Bergqvist M; Elinder E; Bosch A; Lindman H; Einbeigi Z; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Hellstrom M; Johansson H; Wang K; Bergh JCS; Hatschek T; Foukakis T
Breast Cancer Res Treat; 2024 Apr; 204(2):299-308. PubMed ID: 38175448
[TBL] [Abstract][Full Text] [Related]
16. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
Perez EA; Hurvitz SA; Amler LC; Mundt KE; Ng V; Guardino E; Gianni L
Breast Cancer Res; 2014 May; 16(3):R50. PubMed ID: 24887458
[TBL] [Abstract][Full Text] [Related]
17. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
Dang C; Lin N; Moy B; Come S; Sugarman S; Morris P; Abbruzzi A; Chen C; Steingart R; Patil S; Norton L; Winer E; Hudis C
J Clin Oncol; 2010 Jun; 28(18):2982-8. PubMed ID: 20479410
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
Wang C; Zhou Y; Lin Y; Mao F; Guan J; Zhang X; Shen S; Wang X; Zhang Y; Pan B; Zhong Y; Peng L; Cao X; Yao R; Zhou X; Xu C; Xu Y; Sun Q
BMC Cancer; 2022 Mar; 22(1):269. PubMed ID: 35287613
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG).
Berg T; Jensen MB; Jakobsen EH; Al-Rawi S; Kenholm J; Andersson M
Breast; 2020 Dec; 54():242-247. PubMed ID: 33186804
[TBL] [Abstract][Full Text] [Related]
20. Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.
Miolo G; Muraro E; Martorelli D; Lombardi D; Scalone S; Spazzapan S; Massarut S; Perin T; Viel E; Comaro E; Talamini R; Bidoli E; Turchet E; Crivellari D; Dolcetti R
BMC Cancer; 2014 Dec; 14():954. PubMed ID: 25512030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
